Drug Trial Radar · NCT05815485
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia
Last checked: Nov 19, 2026Latest source record: Mar 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
144
Planned (sponsor's estimate)
Start
May 4, 2023
Primary completion
Apr 2026
Study completion Apr 2026
Sponsor
- Lead sponsor
- The University of Texas Medical Branch, GalvestonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A new drug called azeliragon could be used to treat patients with COVID-19 or other pneumonia infections but the researchers don't know. In this study, they are learning the effects of azeliragon patients hospitalized for COVID-19 or pneumonia.
Conditions
- COVID-19
Interventions
AzeliragonDrug
30 mg twice daily for 5 days followed by 20 mg once daily for 5 days or until discharge (whichever is earliest).
PlaceboDrug
Twice daily for 5 days then 1 time daily for 5 days or until discharge (whichever is earliest).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of Adverse Events (AEs) (Phase 2 only)Time frame: Up to 28 days post-treatment
- Death, need for mechanical ventilation or Acute Kidney Injury (AKI) of stage 2 or higher per Kidney Disease Improving Global Outcomes (KDIGO) scale (Phase 3 only)Time frame: Day 14 of hospitalization
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Rush University
Chicago, Illinois
University of Michigan
Ann Arbor, Michigan
University of Texas Medical Branch
Galveston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.